WallStSmart

Boston Scientific Corp (BSX)vsCo-Diagnostics, Inc. Common Stock (CODX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Boston Scientific Corp generates 3311439% more annual revenue ($20.61B vs $622,490). BSX leads profitability with a 17.3% profit margin vs 0.0%. BSX earns a higher WallStSmart Score of 71/100 (B).

BSX

Strong Buy

71

out of 100

Grade: B

Growth: 8.0Profit: 7.0Value: 5.3Quality: 5.5
Piotroski: 4/9

CODX

Hold

41

out of 100

Grade: D

Growth: 7.3Profit: 2.5Value: 5.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BSXSignificantly Overvalued (-25.1%)

Margin of Safety

-25.1%

Fair Value

$46.04

Current Price

$57.61

$11.57 premium

UndervaluedFair: $46.04Overvalued

Intrinsic value data unavailable for CODX.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BSX5 strengths · Avg: 8.6/10
EPS GrowthGrowth
100.0%10/10

Earnings expanding 100.0% YoY

Market CapQuality
$85.62B9/10

Large-cap with strong market position

PEG RatioValuation
0.698/10

Growing faster than its price suggests

Operating MarginProfitability
21.5%8/10

Strong operational efficiency at 21.5%

Free Cash FlowQuality
$1.01B8/10

Generating 1.0B in free cash flow

CODX3 strengths · Avg: 9.3/10
Price/BookValuation
0.2x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
76.7%10/10

Revenue surging 76.7% year-over-year

EPS GrowthGrowth
30.8%8/10

Earnings expanding 30.8% YoY

Areas to Watch

BSX0 concerns · Avg: 0/10

No major concerns identified

CODX4 concerns · Avg: 2.5/10
Market CapQuality
$5.94M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-125.9%2/10

ROE of -125.9% — below average capital efficiency

Free Cash FlowQuality
$-6.33M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : BSX

The strongest argument for BSX centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 17.3% and operating margin at 21.5%. Revenue growth of 11.6% demonstrates continued momentum.

Bull Case : CODX

The strongest argument for CODX centers on Price/Book, Revenue Growth, EPS Growth. Revenue growth of 76.7% demonstrates continued momentum.

Bear Case : BSX

No major red flags identified for BSX, but monitor valuation.

Bear Case : CODX

The primary concerns for CODX are Market Cap, Profit Margin, Return on Equity.

Key Dynamics to Monitor

BSX profiles as a mature stock while CODX is a hypergrowth play — different risk/reward profiles.

CODX carries more volatility with a beta of 1.43 — expect wider price swings.

CODX is growing revenue faster at 76.7% — sustainability is the question.

BSX generates stronger free cash flow (1.0B), providing more financial flexibility.

Bottom Line

BSX scores higher overall (71/100 vs 41/100), backed by strong 17.3% margins and 11.6% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

Co-Diagnostics, Inc. Common Stock

HEALTHCARE · MEDICAL DEVICES · USA

Co-Diagnostics, Inc., a molecular diagnostic company, develops, manufactures, and sells reagents used for diagnostic tests that function by detecting and / or analyzing nucleic acid molecules. The company is headquartered in Salt Lake City, Utah.

Want to dig deeper into these stocks?